×
About 102,514 results

ALLMedicine™ Squamous Cell Carcinoma Center

Research & Reviews  50,467 results

An in vitro study of the effect of 5-ALA-mediated photodynamic therapy on oral squamous...
https://doi.org/10.1186/s12903-020-01239-8
BMC Oral Health; Ma Y, Qu S et. al.

Sep 17th, 2020 - The primary aim of this study was to observe the effect of 5-ALA-mediated photodynamic therapy on oral squamous cell carcinoma in vitro. SCC25 cells were divided into the observation group and the blank control group. Different concentrations of 5...

Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy i...
https://doi.org/10.1186/s13014-020-01666-5
Radiation Oncology (London, England); Gupta T, Sinha S et. al.

Sep 17th, 2020 - To compare long-term disease-related outcomes and late radiation morbidity between intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) in head and neck squamous cell carcinoma (HNSCC) in the setting o...

Concomitant surgery for aortic valve and lung cancer patients in an elder.
https://doi.org/10.1186/s13019-020-01277-x
Journal of Cardiothoracic Surgery; Xu H, Tao T et. al.

Sep 17th, 2020 - The treatment strategy for aortic valve and lung cancer patients includes concomitant or two-stage procedures. Conventional simultaneous operations are usually performed under the median sternotomy. A 72-year-old man was admitted to our hospital a...

Statistical Profiling of Oral Cancer and the Prediction of Outcome.
https://doi.org/10.1111/jop.13110
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology; Wang W, Adeoye J et. al.

Sep 17th, 2020 - The global burden of oral squamous cell carcinoma (OSCC) remains formidable. Identifying factors predictive of aggressive tumour behaviour, disease progression and reduced survival time may assist in early identification of 'high-risk' patients an...

Serum Anti-LRPAP1 is a Common Biomarker for Digestive Organ Cancers and Atherosclerotic...
https://doi.org/10.1111/cas.14652
Cancer Science; Sumazaki M, Shimada H et. al.

Sep 17th, 2020 - Some cancers are related to atherosclerotic diseases, therefore these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening was performed of sera from patients with esophageal squamous cell carci...

see more →

Guidelines  123 results

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M ...

FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA

Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and p...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 30th, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell...

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 30th, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous sq...

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session....

see more →

Drugs  31 results see all →

Clinicaltrials.gov  51,183 results

Bleomycin - bleomycin injection, powder, lyophilized, for solution-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38955939-8d1e-4db2-9aed-3bab72ca5f8f

Dec 26th, 2020 - Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix....

An in vitro study of the effect of 5-ALA-mediated photodynamic therapy on oral squamous...
https://doi.org/10.1186/s12903-020-01239-8
BMC Oral Health; Ma Y, Qu S et. al.

Sep 17th, 2020 - The primary aim of this study was to observe the effect of 5-ALA-mediated photodynamic therapy on oral squamous cell carcinoma in vitro. SCC25 cells were divided into the observation group and the blank control group. Different concentrations of 5...

Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy i...
https://doi.org/10.1186/s13014-020-01666-5
Radiation Oncology (London, England); Gupta T, Sinha S et. al.

Sep 17th, 2020 - To compare long-term disease-related outcomes and late radiation morbidity between intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) in head and neck squamous cell carcinoma (HNSCC) in the setting o...

Concomitant surgery for aortic valve and lung cancer patients in an elder.
https://doi.org/10.1186/s13019-020-01277-x
Journal of Cardiothoracic Surgery; Xu H, Tao T et. al.

Sep 17th, 2020 - The treatment strategy for aortic valve and lung cancer patients includes concomitant or two-stage procedures. Conventional simultaneous operations are usually performed under the median sternotomy. A 72-year-old man was admitted to our hospital a...

Statistical Profiling of Oral Cancer and the Prediction of Outcome.
https://doi.org/10.1111/jop.13110
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology; Wang W, Adeoye J et. al.

Sep 17th, 2020 - The global burden of oral squamous cell carcinoma (OSCC) remains formidable. Identifying factors predictive of aggressive tumour behaviour, disease progression and reduced survival time may assist in early identification of 'high-risk' patients an...

see more →

News  667 results

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M ...

FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA

Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and p...

Israeli medical device maker Alpha Tau raises $26 million to fund trials
https://www.reuters.com/article/uk-tech-fundraising-alpha-tau/israeli-medical-device-maker-alpha-tau-raises-26-million-to-fund-trials-idUSKBN23B1NX

Jun 4th, 2020 - JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials. Alpha Tau...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 30th, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell...

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 30th, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous sq...

see more →

Patient Education  43 results see all →